Original Article
Efficacy of Leflunomide 100mg Weekly Compared to Low Dose Methotrexate in Patients With Active Rheumatoid Arthritis. Double Blind, Randomized Clinical Trial
Eficacia de leflunomida 100mg semanales comparado con dosis bajas de metotrexate en pacientes con artritis reumatoide activa. Estudio clínico doble ciego aleatorizado
Read
11196
Timeswas read the article
3058
Total PDF
8138
Total HTML
| Year/Month | Html | Total | |
|---|---|---|---|
| 2025 6 | 5 | 37 | 42 |
| 2025 5 | 180 | 114 | 294 |
| 2025 4 | 164 | 37 | 201 |
| 2025 3 | 124 | 45 | 169 |
| 2025 2 | 102 | 41 | 143 |
| 2025 1 | 93 | 45 | 138 |
| 2024 12 | 66 | 35 | 101 |
| 2024 11 | 102 | 60 | 162 |
| 2024 10 | 69 | 42 | 111 |
| 2024 9 | 96 | 22 | 118 |
| 2024 8 | 111 | 38 | 149 |
| 2024 7 | 88 | 38 | 126 |
| 2024 6 | 128 | 41 | 169 |
| 2024 5 | 88 | 34 | 122 |
| 2024 4 | 98 | 22 | 120 |
| 2024 3 | 75 | 38 | 113 |
| 2024 2 | 80 | 47 | 127 |
| 2024 1 | 73 | 27 | 100 |
| 2023 12 | 75 | 34 | 109 |
| 2023 11 | 70 | 30 | 100 |
| 2023 10 | 104 | 48 | 152 |
| 2023 9 | 137 | 44 | 181 |
| 2023 8 | 64 | 19 | 83 |
| 2023 7 | 76 | 32 | 108 |
| 2023 6 | 63 | 27 | 90 |
| 2023 5 | 66 | 18 | 84 |
| 2023 4 | 85 | 27 | 112 |
| 2023 3 | 93 | 42 | 135 |
| 2023 2 | 104 | 32 | 136 |
| 2023 1 | 46 | 25 | 71 |
| 2022 12 | 78 | 47 | 125 |
| 2022 11 | 96 | 36 | 132 |
| 2022 10 | 77 | 36 | 113 |
| 2022 9 | 53 | 45 | 98 |
| 2022 8 | 87 | 36 | 123 |
| 2022 7 | 79 | 50 | 129 |
| 2022 6 | 76 | 40 | 116 |
| 2022 5 | 68 | 40 | 108 |
| 2022 4 | 78 | 56 | 134 |
| 2022 3 | 60 | 60 | 120 |
| 2022 2 | 90 | 44 | 134 |
| 2022 1 | 84 | 43 | 127 |
| 2021 12 | 53 | 35 | 88 |
| 2021 11 | 71 | 54 | 125 |
| 2021 10 | 71 | 57 | 128 |
| 2021 9 | 64 | 44 | 108 |
| 2021 8 | 92 | 47 | 139 |
| 2021 7 | 64 | 43 | 107 |
| 2021 6 | 57 | 47 | 104 |
| 2021 5 | 68 | 48 | 116 |
| 2021 4 | 153 | 109 | 262 |
| 2021 3 | 84 | 36 | 120 |
| 2021 2 | 52 | 29 | 81 |
| 2021 1 | 61 | 20 | 81 |
| 2020 12 | 58 | 21 | 79 |
| 2020 11 | 46 | 42 | 88 |
| 2020 10 | 13 | 15 | 28 |
| 2020 9 | 43 | 33 | 76 |
| 2020 8 | 30 | 16 | 46 |
| 2020 7 | 44 | 29 | 73 |
| 2020 6 | 55 | 16 | 71 |
| 2020 5 | 59 | 23 | 82 |
| 2020 4 | 59 | 17 | 76 |
| 2020 3 | 9 | 11 | 20 |
| 2019 1 | 1 | 0 | 1 |
| 2018 5 | 4 | 1 | 5 |
| 2018 4 | 57 | 7 | 64 |
| 2018 3 | 57 | 7 | 64 |
| 2018 2 | 36 | 6 | 42 |
| 2018 1 | 40 | 7 | 47 |
| 2017 12 | 46 | 12 | 58 |
| 2017 11 | 41 | 6 | 47 |
| 2017 10 | 33 | 5 | 38 |
| 2017 9 | 70 | 5 | 75 |
| 2017 8 | 73 | 8 | 81 |
| 2017 7 | 69 | 7 | 76 |
| 2017 6 | 91 | 16 | 107 |
| 2017 5 | 100 | 11 | 111 |
| 2017 4 | 91 | 6 | 97 |
| 2017 3 | 86 | 14 | 100 |
| 2017 2 | 48 | 9 | 57 |
| 2017 1 | 63 | 3 | 66 |
| 2016 12 | 80 | 19 | 99 |
| 2016 11 | 114 | 5 | 119 |
| 2016 10 | 114 | 10 | 124 |
| 2016 9 | 173 | 5 | 178 |
| 2016 8 | 116 | 2 | 118 |
| 2016 7 | 41 | 7 | 48 |
| 2016 1 | 3 | 0 | 3 |
| 2015 12 | 2 | 0 | 2 |
| 2015 10 | 2 | 0 | 2 |
| 2015 9 | 1 | 0 | 1 |
| 2015 8 | 2 | 14 | 16 |
| 2015 7 | 17 | 6 | 23 |
| 2015 6 | 54 | 8 | 62 |
| 2015 5 | 60 | 14 | 74 |
| 2015 4 | 51 | 6 | 57 |
| 2015 3 | 52 | 5 | 57 |
| 2015 2 | 46 | 6 | 52 |
| 2015 1 | 59 | 10 | 69 |
| 2014 12 | 49 | 11 | 60 |
| 2014 11 | 44 | 10 | 54 |
| 2014 10 | 40 | 9 | 49 |
| 2014 9 | 31 | 13 | 44 |
| 2014 8 | 45 | 11 | 56 |
| 2014 7 | 35 | 19 | 54 |
| 2014 6 | 48 | 6 | 54 |
| 2014 5 | 46 | 10 | 56 |
| 2014 4 | 56 | 11 | 67 |
| 2014 3 | 54 | 14 | 68 |
| 2014 2 | 38 | 11 | 49 |
| 2014 1 | 49 | 13 | 62 |
| 2013 12 | 39 | 9 | 48 |
| 2013 11 | 30 | 11 | 41 |
| 2013 10 | 39 | 14 | 53 |
| 2013 9 | 38 | 12 | 50 |
| 2013 8 | 104 | 11 | 115 |
| 2013 7 | 61 | 12 | 73 |
| 2013 6 | 44 | 7 | 51 |
| 2013 5 | 40 | 17 | 57 |
| 2013 4 | 43 | 9 | 52 |
| 2013 3 | 45 | 13 | 58 |
| 2013 2 | 33 | 7 | 40 |
| 2013 1 | 31 | 16 | 47 |
| 2012 12 | 33 | 16 | 49 |
| 2012 11 | 44 | 32 | 76 |
| 2012 10 | 29 | 21 | 50 |
Show all
